Could Amgen's Latest Bad News Boost the Chances of More Acquisitions?

You've probably heard that the best way to deliver bad news is to sandwich it in the middle of positive news. Amgen (NASDAQ: AMGN) used this approach so well last week that the bad news was hard to spot.

The big biotech issued a press release on Sept. 12 with the headline "Amgen Highlights New Data from Kyprolis (cafilzomib) and Oncology Pipeline at IMW 2019," with IMW2019 referring to the International Myeloma Workshop held in Boston last week. Most of this press release related to updates about Amgen's clinical studies featuring Kyprolis.